Regarding: A global anti-B cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome

Pediatric Nephrology (2021)Cite this article

The Original Article is available

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

US$ 39.95

Tax calculation will be finalised during checkout.

References

  1. 1.

    Dossier C, Prim B, Moreau C, Kwon T, Maisin A, Nathanson S, De Gennes C, Barsotti K, Bourrassi A, Hogan J, Deschênes G (2020) A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. Pediatr Nephrol. https://doi.org/10.1007/s00467-020-04811-0

  2. 2.

    Said R, Tsimberidou AM (2017) Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. Expert Opin Biol Ther 17:1463–1470

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Tam C, Kuss B, Opat S, Boulos J, Marlton P (2017) Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil. Intern Med J 47(Suppl 4):5–10

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Intercollegiate Faculty of Biotechnology of the University of Gdańsk and the Medical, University of Gdańsk, Gdańsk, Poland

    Alan Majeranowski & Marcin Okrój

Authors
  1. Alan Majeranowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcin Okrój
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan Majeranowski.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Majeranowski, A., Okrój, M. Regarding: A global anti-B cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. Pediatr Nephrol (2021). https://doi.org/10.1007/s00467-021-04981-5

Download citation